First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM).

被引：0
|
作者：
Plummer, R.
Lorigan, P.
Evans, J.
Steven, N.
Middleton, M.
Wilson, R.
Snow, K.
Dewji, R.
Calvert, H.
机构：
[1] No Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[2] Chrisite Hosp, Manchester, Lancs, England
[3] Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland
[4] Inst Canc Studies, Birmingham, W Midlands, England
[5] Canc Res UK, Oxford, England
[6] Queens Univ Belfast, Belfast, Antrim, North Ireland
[7] Pfizer GRD, Sandwich, Kent, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：456S / 456S
页数：1
相关论文
共 50 条
  • [21] A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors
    Gao, Bo
    Voskoboynik, Mark
    Cooper, Adam
    Wilkinson, Kate
    Hoon, Siao
    Hsieh, Chih-Yi
    Cai, Suixiong
    Tian, Ye Edward
    Bao, Jun
    Ma, Ning
    Wang, Chen
    Zhang, Ming
    Li, Baoyue
    Guo, Mingchuan
    Zhou, Ruiyu
    Wang, Xiaozhu
    Xu, Cong
    de Souza, Paul
    CANCER, 2023, 129 (07) : 1041 - 1050
  • [22] Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer.
    Drew, Y.
    Ledermann, J. A.
    Jones, A.
    Hall, G.
    Jayson, G. C.
    Highley, M.
    Rea, D.
    Glasspool, R. M.
    Halford, S. E. R.
    Crosswell, G.
    Colebrook, S.
    Boddy, A. V.
    Curtin, N. J.
    Plummer, E. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors.
    Tan, A. R.
    Toppmeyer, D.
    Stein, M. N.
    Moss, R. A.
    Gounder, M.
    Lindquist, D. C.
    Ji, J. J.
    Chen, A. P.
    Egorin, M. J.
    Kiesel, B.
    Beumer, J. H.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Phase I pharmacolkinetic (PK) and pharmacodynamic (PD) evaluation of an oral small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), Ku in patients (p) with advanced tumours
    de Bono, J. S.
    Fong, P. C.
    Boss, D.
    Spicer, J.
    Roelvink, M.
    Tutt, A.
    Mortimer, P.
    O'Connor, M.
    Schellens, J. H. M.
    Kaye, S. B.
    EJC SUPPLEMENTS, 2006, 4 (12): : 153 - 153
  • [25] Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
    O'Shaughnessy, J.
    Osborne, C.
    Pippen, J.
    Yoffe, M.
    Patt, D.
    Monaghan, G.
    Rocha, C.
    Ossovskaya, V.
    Sherman, B.
    Bradley, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [26] First-in-human, phase 1/2 study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors
    Samnotra, Vivek
    Moroz, Veronica
    Shtessel, Luda
    Kuchimanchi, Mita
    Hanafin, Patrick
    Pannirselvam, Malar
    Bhaskar, Aishwarya
    Liu, Andrew
    Yuzugullu, Haluk
    Barve, Minal
    Sommerhalder, David
    Yap, Timothy
    Sanicola-Nadel, Michele
    CANCER RESEARCH, 2024, 84 (07)
  • [27] Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial
    O'Shaughnessy, J.
    Osborne, C.
    Pippen, J.
    Yoffe, M.
    Patt, D.
    Monaghan, G.
    Rocha, C.
    Ossovskaya, V.
    Sherman, B.
    Bradley, C.
    EJC SUPPLEMENTS, 2009, 7 (03): : 7 - 7
  • [28] Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
    Lotte van Andel
    Z. Zhang
    S. Lu
    V. Kansra
    S. Agarwal
    L. Hughes
    M. M. Tibben
    A. Gebretensae
    L. Lucas
    M. J. X. Hillebrand
    H. Rosing
    J. H. M. Schellens
    J. H. Beijnen
    Investigational New Drugs, 2017, 35 : 751 - 765
  • [29] Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
    van Andel, Lotte
    Zhang, Z.
    Lu, S.
    Kansra, V.
    Agarwal, S.
    Hughes, L.
    Tibben, M. M.
    Gebretensae, A.
    Lucas, L.
    Hillebrand, M. J. X.
    Rosing, H.
    Schellens, J. H. M.
    Beijnen, J. H.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 751 - 765
  • [30] Olaparib, a poly (ADP-ribose) polymerase (PARP) Inhibitor, in Combination with Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (RM-HNSCC): A Single-Arm, Phase 2 Trial
    Oppelt, P.
    Ley, J.
    Liu, J.
    Adkins, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E42 - E43
12345